Esperion Therapeutics, Inc.ESPRNASDAQ
Loading
Year-over-year earnings per share growth rate
3Y CAGR
+221.2%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
33.1x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 262.50% |
| Q3 2025 | -561.16% |
| Q2 2025 | 88.48% |
| Q1 2025 | -90.91% |
| Q4 2024 | 26.67% |
| Q3 2024 | 54.55% |
| Q2 2024 | -191.67% |
| Q1 2024 | 172.00% |
| Q4 2023 | -35.14% |
| Q3 2023 | 19.57% |
| Q2 2023 | 59.65% |
| Q1 2023 | -22.58% |
| Q4 2022 | 7.92% |
| Q3 2022 | 20.47% |
| Q2 2022 | -9.48% |
| Q1 2022 | 34.46% |
| Q4 2021 | 32.44% |
| Q3 2021 | -56.89% |
| Q2 2021 | 52.29% |
| Q1 2021 | 10.03% |
| Q4 2020 | -26.71% |
| Q3 2020 | -168.22% |
| Q2 2020 | 258.45% |
| Q1 2020 | -25.66% |
| Q4 2019 | 10.32% |
| Q3 2019 | -25.37% |
| Q2 2019 | -161.66% |
| Q1 2019 | 245.54% |
| Q4 2018 | -20.43% |
| Q3 2018 | -8.77% |
| Q2 2018 | 1.16% |
| Q1 2018 | -20.14% |
| Q4 2017 | 22.58% |
| Q3 2017 | 3.12% |
| Q2 2017 | -6.67% |
| Q1 2017 | -40.63% |
| Q4 2016 | -66.23% |
| Q3 2016 | -24.19% |
| Q2 2016 | 4.62% |
| Q1 2016 | -12.07% |